No Data
Travere Therapeutics to Present at Upcoming Investor Conferences
Travere Therapeutics Is Maintained at Sector Outperform by Scotiabank
Travere Therapeutics Price Target Raised to $27.00/Share From $23.00 by Scotiabank
Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
A Quick Look at Today's Ratings for Travere Therapeutic(TVTX.US), With a Forecast Between $20 to $33
Express News | Travere Therapeutics: Entered Amended & Restated Agreement of Upto $100 Mln in Common Stock Offering
No Data
No Data